Last reviewed · How we verify
Congenital myotonia, autosomal dominant form
Approved treatments
- Anamidol
Anamidol binds to androgen receptors in the body, triggering a cascade of downstream effects that promote muscle growth and development. - Fluotestin
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Congenital myotonia, autosomal dominant form patent landscape — cliff calendar, originator estates, attackable patents
- Congenital myotonia, autosomal dominant form treatment landscape brief
- Congenital myotonia, autosomal dominant form treatment updates RSS
Frequently asked questions about Congenital myotonia, autosomal dominant form
What drugs treat Congenital myotonia, autosomal dominant form?
Tracked treatments include Anamidol, Fluotestin.
What is the treatment for Congenital myotonia, autosomal dominant form?
Standard treatment for Congenital myotonia, autosomal dominant form includes Anamidol, Fluotestin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Congenital myotonia, autosomal dominant form patent cliff · Congenital myotonia, autosomal dominant form CI report
- Treatment: Anamidol
- Treatment: Fluotestin
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing